AU Patent

AU2023248145B2 — Ophthalmic suspension composition

Assigned to Bausch and Lomb Inc · Expires 2025-08-28 · 1y expired

What this patent protects

#$%^&*AU2023248145B220250828.pdf##### ABSTRACT OF THE DISCLOSURE A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles …

USPTO Abstract

#$%^&*AU2023248145B220250828.pdf##### ABSTRACT OF THE DISCLOSURE A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dgo < 5 pm and Dv5 o< 1 pm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition. 12 Oct 2023 ABSTRACT OF THE DISCLOSURE A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90 <5 µm and Dv50< 1 µm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition. 2023248145

Drugs covered by this patent

Patent Metadata

Patent number
AU2023248145B2
Jurisdiction
AU
Classification
—
Expires
2025-08-28
Drug substance claim
No
Drug product claim
No
Assignee
Bausch and Lomb Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.